NO981578L - FremgangsmÕte for hemming av plasminogenaktivatorhemmer I - Google Patents

FremgangsmÕte for hemming av plasminogenaktivatorhemmer I

Info

Publication number
NO981578L
NO981578L NO981578A NO981578A NO981578L NO 981578 L NO981578 L NO 981578L NO 981578 A NO981578 A NO 981578A NO 981578 A NO981578 A NO 981578A NO 981578 L NO981578 L NO 981578L
Authority
NO
Norway
Prior art keywords
plasminogen activator
activator inhibitor
inhibiting plasminogen
inhibiting
hexamethylenimine
Prior art date
Application number
NO981578A
Other languages
English (en)
Other versions
NO981578D0 (no
Inventor
David Thompson Berg
Brian William Grinnell
Mark Alan Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO981578L publication Critical patent/NO981578L/no
Publication of NO981578D0 publication Critical patent/NO981578D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Fremgangsmåte for å hemme plasminogenaktivatorhemmer l, omfatter administrering til et menneske som har behov for dette av en effektiv mengde av en forbindelse med formel (I), hvor R1 og R3 uavhengig av hverandre er hydrogen, -CH3, (a) eller (b), og hvori Ar eventuelt er substituert fenyl; R2 blir valgt fra gruppen bestående av pyrrolidin, heksametylenimin og piperidin; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO981578A 1995-10-10 1998-04-07 FremgangsmÕte for hemming av plasminogenaktivatorhemmer I NO981578D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US501595P 1995-10-10 1995-10-10
PCT/US1996/016059 WO1997013511A1 (en) 1995-10-10 1996-10-07 Methods of inhibiting plasminogen activator inhibitor 1

Publications (2)

Publication Number Publication Date
NO981578L true NO981578L (no) 1998-04-07
NO981578D0 NO981578D0 (no) 1998-04-07

Family

ID=21713702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981578A NO981578D0 (no) 1995-10-10 1998-04-07 FremgangsmÕte for hemming av plasminogenaktivatorhemmer I

Country Status (20)

Country Link
US (1) US5731328A (no)
EP (1) EP0854715B1 (no)
JP (1) JPH11513665A (no)
KR (1) KR19990064099A (no)
CN (1) CN1199337A (no)
AR (1) AR003812A1 (no)
AT (1) ATE255414T1 (no)
AU (1) AU716655B2 (no)
CA (1) CA2234404A1 (no)
CO (1) CO4750819A1 (no)
CZ (1) CZ106098A3 (no)
DE (1) DE69630969T2 (no)
EA (1) EA001003B1 (no)
ES (1) ES2211981T3 (no)
HU (1) HUP9802348A3 (no)
NO (1) NO981578D0 (no)
NZ (1) NZ319948A (no)
PL (1) PL326294A1 (no)
WO (1) WO1997013511A1 (no)
ZA (1) ZA968444B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2006088011A1 (ja) * 2005-02-15 2006-08-24 Tokai University Educational System プラスミノーゲンアクチベーターインヒビター－１阻害剤
EP1942930A2 (en) * 2005-10-11 2008-07-16 Amano Enzyme USA., Ltd. Enzyme inhibitors of pai-1
CN101544138B (zh) * 2008-03-26 2012-05-23 山东新北洋信息技术股份有限公司 热转印打印机碳带回收装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
PT664121E (pt) * 1993-12-21 2002-03-28 Lilly Co Eli Inibicao da oxidacao de ldl e aterosclerose

Also Published As

Publication number Publication date
KR19990064099A (ko) 1999-07-26
HUP9802348A3 (en) 1999-11-29
US5731328A (en) 1998-03-24
NZ319948A (en) 2000-06-23
PL326294A1 (en) 1998-09-14
AR003812A1 (es) 1998-09-09
ATE255414T1 (de) 2003-12-15
AU716655B2 (en) 2000-03-02
HUP9802348A2 (hu) 1999-08-30
CZ106098A3 (cs) 1999-03-17
WO1997013511A1 (en) 1997-04-17
ZA968444B (en) 1998-04-07
EA001003B1 (ru) 2000-08-28
EP0854715B1 (en) 2003-12-03
EP0854715A4 (en) 2001-12-19
ES2211981T3 (es) 2004-07-16
DE69630969T2 (de) 2004-10-21
CO4750819A1 (es) 1999-03-31
DE69630969D1 (de) 2004-01-15
JPH11513665A (ja) 1999-11-24
CA2234404A1 (en) 1997-04-17
EP0854715A1 (en) 1998-07-29
EA199800366A1 (ru) 1998-10-29
NO981578D0 (no) 1998-04-07
AU7259696A (en) 1997-04-30
CN1199337A (zh) 1998-11-18

Similar Documents

Publication Publication Date Title
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
DK0659416T3 (da) Inhibering af seborE og acne
NO944930D0 (no) Hemming av dysfunksjonell uterin blödning
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
NO20000750L (no) FremgangsmÕte for Õ redusere blodplatetall
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO983452L (no) FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application